FCRL5/FcRH5/IRTA2 Antibody [Alexa Fluor® 350]

• Reactivity: Mu
• Applications: Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 350

FCRL5/FcRH5/IRTA2 Antibody [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FCRL5/FcRH3
  Gln27-Ala496 (predicted)
  Accession # NP_899045
• Specificity: Detects mouse FCRL5/FcRH3 in direct ELISAs. In direct ELISAs, less than 1% cross-reactivity with recombinant human FCRL5 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCRL5/FcRH5/IRTA2 Antibody [Alexa Fluor® 350]

• BXMAS1
• BXMAS1MGC119592
• CD307
• CD307e antigen
• CD307e
• DKFZp667E2019
• DKFZp667F216
• Fc receptor homolog 5
• Fc receptor-like 5
• Fc receptor-like protein 5
• FcRH5
• FCRH5MGC119593
• FCRL5
• FcR-like protein 5
• FLJ00333
• FLJ00397
• IFGP5
• Immune receptor translocation-associated protein 2
• immunoglobulin superfamily receptor translocation associated 2 (IRTA2)
• IRTA2
• IRTA2MGC119590
• PRO820

Background

Fc Receptor-Like 5 (FCRL5), also known as FcRH3 (FcRH5 in human), IRTA2, and CD307e, is a 90‑95 kDa member of the FCRL family of proteins whose amino acid (aa) sequence is reminiscent of that for classical Fc receptors. FCLR molecules are type 1 transmembrane proteins that contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage, and can either promote or inhibit B cell proliferation and activation (1, 2, 3). Mature mouse FCRL5 consists of a 470 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 79 aa cytoplasmic region. The ECD contains five Ig-like domains, while the cytoplasmic region possesses one ITAM-like motif and one immunotyrosine inhibitory motif (ITIM) (1, 3, 4). There are two major alleles for FCLR5 in mouse. The first was just described, and is found in BALB/c plus NZB mouse strains. The second is found in C57BL/6 mice, and differs by eleven scattered aa in the ECD. This creates one additional N-linked glycosylation site, and increases the SDS‑PAGE MW by 5 kDa (3). Alternate splicing of mouse FCRL5 generates at least one additional isoform that lacks the first Ig-like domain (aa 3‑90 of the mature molecule) (4). Human FCRL5, by contrast, contains up to nine Ig-like domains in a highly variable ECD, and over common regions, mouse and human FCRL5 share 49% aa sequence identity. CRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood, and is particularly noted to be expressed on T‑independent marginal zone and B1 B cells (3-8). Its ligation inhibits signaling through the B cell antigen receptor (9). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (10). FCRL5 on B cells functions as a receptor for the orthopoxvirus MHC class I-like protein OMCP (11). And based on the literature and R&D Systems testing, both mouse and human FCRL5 will bind to purified IgG with high affinity (5). In human, the FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies. Notably, the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities, and is up‑regulated on tumor cells in some types of B cell malignancies (5, 7, 12‑14). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (13, 15).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.